The Community Acquired Pneumonia drugs in development market research report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Community Acquired Pneumonia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued products.

GlobalData tracks 27 drugs in development for Community Acquired Pneumonia by 26 companies/universities/institutes. The top development phase for Community Acquired Pneumonia is phase iii with seven drugs in that stage. The Community Acquired Pneumonia pipeline has 26 drugs in development by companies and one by universities/ institutes. Some of the companies in the Community Acquired Pneumonia pipeline products market are: Wockhardt, Iterum Therapeutics and Aptarion Biotech.

The key targets in the Community Acquired Pneumonia pipeline products market include 23S Ribosomal RNA (23S rRNA), DNA Gyrase (EC, and DNA Topoisomerase IV (EC

The key mechanisms of action in the Community Acquired Pneumonia pipeline product include 23S Ribosomal RNA (23S rRNA) Inhibitor with four drugs in Pre-Registration. The Community Acquired Pneumonia pipeline products include nine routes of administration with the top ROA being Intravenous and seven key molecule types in the Community Acquired Pneumonia pipeline products market including Small Molecule, and Recombinant Protein.

Community Acquired Pneumonia overview

Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

For a complete picture of Community Acquired Pneumonia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.